INMDHealthcare · Medical DevicesThe 5 Wall Street analysts covering InMode Ltd. hold a median 12-month price target of $17 — +9.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores InMode Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (31): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 May 2026 | Baird | Maintains | Neutral | — |
| 7 May 2026 | Baird | Maintains | Neutral | $17 → $14 |
| 7 May 2026 | Barclays | Maintains | Overweight | — |
| 7 May 2026 | Barclays | Maintains | Overweight | $21 → $19 |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 6 Nov 2025 | UBS | Maintains | Neutral | — |
| 10 Oct 2025 | Canaccord Genuity | Maintains | Hold | — |
| 10 Oct 2025 | Needham | Reiterates | Hold | — |
| 30 July 2025 | Barclays | Maintains | Overweight | — |
| 30 July 2025 | Needham | Reiterates | Hold | — |
| 11 July 2025 | Canaccord Genuity | Maintains | Hold | — |
| 30 Apr 2025 | Barclays | Maintains | Overweight | — |
| 29 Apr 2025 | BTIG | Downgrade | Neutral | — |
| 29 Apr 2025 | Canaccord Genuity | Maintains | Hold | — |
| 29 Apr 2025 | UBS | Maintains | Neutral | — |
| 28 Apr 2025 | Needham | Reiterates | Hold | — |
| 14 Apr 2025 | Jefferies | Maintains | Hold | — |
| 14 Apr 2025 | Needham | Reiterates | Hold | — |
| 9 Apr 2025 | Needham | Reiterates | Hold | — |
| 5 Feb 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 53% of US stocks
Cheaper than 49% of US stocks
Cheaper than 59% of US stocks
Cheaper than 53% of US stocks
Higher than 65% of US stocks
Higher than 13% of US stocks
Higher than 87% of US stocks
Higher than 69% of US stocks
Higher than 83% of US stocks
Higher than 69% of US stocks
Higher than 82% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own InMode Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
InMode Ltd. reported its second quarter 2026 financial results, with GAAP revenues of $95.6 million, consistent with the same period in 2025.
Why it matters — The flat revenue compared to the prior year quarter offers InMode shareholders a key benchmark on growth momentum heading into the second half of 2026.
Steel Partners, a significant shareholder of InMode, issued a letter urging shareholders to vote against Proposal 1 (re-election of Dr. Hadar Ron) and Proposal 4 (Extraordinary Special Committee Compensation) at the company's July 30 Annual General Meeting.
Why it matters — The public opposition from a major shareholder on key governance and compensation issues signals potential discord within InMode's investor base ahead of the annual meeting.
The 5 Wall Street analysts covering InMode Ltd. have a median 12-month price target of $17, with estimates ranging from $15 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering InMode Ltd., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InMode Ltd. 76 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, InMode Ltd. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +9.6% from the last close, and Ticker Nerd's factor model ranks InMode Ltd. 76 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering InMode Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $17 over the next 12 months.
InMode Ltd. returned +6.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
InMode Ltd. designs, develops, manufactures, and markets innovative medical aesthetic devices powered by proprietary radiofrequency technology.
The most recent item we track (PRNewsWire, 5 Aug 2026): "InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025". InMode Ltd. reported its second quarter 2026 financial results, with GAAP revenues of $95.6 million, consistent with the same period in 2025.
InMode Ltd. designs, develops, manufactures, and markets innovative medical aesthetic devices powered by proprietary radiofrequency technology. The company specializes in minimally invasive platforms for procedures like liposuction with skin tightening, body and face contouring, ablative skin rejuvenation, and treatments for women's health conditions. Its non-invasive products address permanent hair reduction, facial rejuvenation, wrinkle reduction, cellulite treatment, skin texture improvement, and superficial vascular or pigmented lesions. Additionally, hands-free devices target skin tightening, fat reduction, and muscle stimulation. InMode Ltd. serves specialties including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. Products reach physicians and clinics in the United States, Canada, Europe, Japan, Australia, India, and other international markets through a network of distributors. Founded in 2008 and headquartered in Yokneam, Israel, InMode Ltd. plays a key role in advancing radiofrequency-based solutions for aesthetic and wellness procedures worldwide.
CEO Mr. Moshe Mizrahy · 660 employees · Israel · https://www.inmodemd.com